SCHEMBL5247553

SCHEMBL5247553

O=C(CN1CCC(CN2Cc3ccccc3C2=O)CC1)c1ccc2c(c1)OCCO2

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 1/20 0.69
HTR2A P28223 1/20 0.69
TMEM97 Q5BJF2 1/20 0.69
RAB9A P51151 8/20 0.54
NPC1 O15118 6/20 0.54
ALDH1A1 P00352 6/20 0.54
LMNA P02545 6/20 0.54
KDM4E B2RXH2 2/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
HSP90AA1 P07900 2/20 0.52
PAX8 Q06710 1/20 0.52
BCHE P06276 2/20 0.50
ACHE P22303 2/20 0.50
KMT2A Q03164 2/20 0.48
HTT P42858 4/20 0.48
MAPT P10636 4/20 0.48
USP2 O75604 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
HSD17B10 Q99714 1/20 0.48
XBP1 P17861 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5251978 0.99 HTR1A (0.68) HTR1AHTR2ATMEM97RAB9ANPC1
SCHEMBL5253082 0.94 HTR1A (0.69) HTR1AHTR2ATMEM97RAB9ANPC1
Hydrochloric Acid SCHEMBL5248906 0.94 HTR1A (0.68) HTR1AHTR2ATMEM97RAB9ANPC1
SCHEMBL5251937 0.84 HTR1A (0.74) HTR1AHTR2ATMEM97ALDH1A1BCHE
SCHEMBL5250232 0.84 HTR1A (0.84) HTR1AHTR2ATMEM97RAB9AALDH1A1
SCHEMBL5250064 0.83 HTR2A (0.80) HTR1AHTR2ATMEM97RAB9ANPC1
Hydrochloric Acid SCHEMBL5250306 0.83 HTR1A (0.73) HTR1AHTR2ATMEM97NPC1ALDH1A1
Hydrochloric Acid SCHEMBL5250528 0.83 HTR1A (0.82) HTR1AHTR2ATMEM97RAB9AALDH1A1
SCHEMBL5248922 0.82 HTR2A (0.81) HTR1AHTR2ATMEM97RAB9AALDH1A1
Roluperidone SCHEMBL5252391 0.82 HTR2A (1.00) HTR1AHTR2ATMEM97RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1260512-B1 NOVEL CYCLIC AMIDE DERIVATIVES MITSUBISHI PHARMA CORP (JP) 2007-07-04 EP disclosed
US-7166617-B2 Cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2007-01-23 US disclosed
US-20030212094-A1 Novel cyclic amide derivatives MITSUBISHI PHARMA CORPORATION (JP) 2003-11-13 US disclosed
EP-1260512-A1 NOVEL CYCLIC AMIDE DERIVATIVES Mitsubishi Pharma Corporation (JP) 2002-11-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030212094-A1 Novel cyclic amide derivatives SIGMAR1, OPRM1, OPRD1 HTR1A 79/4885HTR2A 153/4885TMEM97 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.